Iridium’s vote clears one gate; the merger spread still fails 10/5

Summary: Iridium shareholders approved Rocket Lab’s acquisition, removing the vote condition; 81% of shares entitled to vote supported it. Rocket Lab has also completed the $1.944 billion ATM equity raise intended to fund the cash leg, but the stated $54 per-share value is still only $27 cash plus a floating Rocket Lab share leg and remaining approvals before a mid-2027 target close. Against IRDM’s $48.72 after-hours reference, the nominal in-collar base is +10.8%, while a deal-break stress is -41.5%. On subjective probabilities, expected value only narrowly exceeds a simple nine-month Treasury carry benchmark before costs and taxes, while gross reward/risk is 0.26:1. Reject / no trade.

Research timestamp: September 25, 2026, 13:31 Singapore time (05:31 UTC). U.S. regular trading has not begun. The latest completed IRDM regular close was $48.89 on Sep. 24; its later $48.72 observation at 7:45 p.m. EDT is reference-only. RKLB closed at $73.61, with a separate $74.31 after-hours observation at 7:59 p.m. EDT. None is an executable entry or a synchronized basket quote.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Iridium (IRDM)	Long common	Vote condition cleared and Rocket Lab reports its cash funding is secured, but the market still prices a long-dated cash-and-stock deal with a floating acquirer leg	Sep. 24 issuer vote result; Sep. 15 financing filing; Sep. 24 close and later extended-hours marks	Remaining HSR/FCC/foreign approvals; target close mid-2027	Vote support is known; current short/borrow, fund-flow and holder-positioning data are not	Reject: +10.8% nominal reference base versus -41.5% break stress; 0.26:1 gross ratio	Nasdaq common; current spread/depth and a synchronized RKLB/IRDM execution package unverified	Regulatory failure, RKLB volatility, 29.3M-share ATM dilution and long carry
2	Select Water Solutions (WTTR)	Long screen	Announced $700M cash-and-stock purchase of Pilot against seller-guided 2027 EBITDA and synergy claims	Sep. 24 issuer agreement; Sep. 24 closing reference	Expected Q4 2026 close and 2027 volume ramp	Deal financing and purchase-price stock true-up create claims; direct flows unavailable	Reject: acquisition presentation is not evidence of per-share accretion	NYSE common; close feeds agree at $19.53, but volume totals differ (~1.70M vs 2.02M)	$600M cash requirement, leverage/financing and seller volume/EBITDA assumptions
3	Archer Aviation (ACHR)	Long screen	HSR waiting period for the Boeing subsidiary acquisition expired, but other closing conditions and eVTOL commercialization remain	Sep. 24 issuer/SEC release; Sep. 24 closing reference	Remaining approvals and expected year-end 2026 closing	No current ownership, short, options or flow audit	Reject: a regulatory milestone does not bound venture-like operating downside	NYSE common; history feeds were near $5.71-$5.72 and ~28.7M shares; no live execution audit	Pre-revenue commercialization, financing/dilution and remaining approval risk

Selected opportunity: IRDM, for information value only; it is not a qualified long.

Why this one now: The Sep. 24 vote is a material state change: 99.6% of votes cast, representing 81.0% of outstanding shares entitled to vote, approved the agreement. Unlike a generic merger headline, the primary agreement provides a precise cash/stock formula that can be tested against a dated reference and a real downside branch.

What should surprise the reader: The $54 figure is not a $54 cash floor. Only $27 is cash. The other half is delivered as Rocket Lab shares using a 10-trading-day VWAP measured shortly before closing; outside the collar, the share value moves with RKLB. Even if the transaction closes, the common holder can lose money if that stock leg falls or if the deal breaks.

Why This Is the Best Opportunity Right Now

This is the highest-information fresh long screen, not the strongest executable opportunity. IRDM combines a new, quantified shareholder vote with a filed merger formula and an observable regulatory ladder. WTTR has an interesting private-asset acquisition, but its 2027 EBITDA, synergies, leverage and volume statements are buyer/seller estimates, and the Sep. 24 close agrees across the checked feeds while reported volume differs by about 19%. ACHR cleared one antitrust waiting period, but the release says other approvals remain and does not supply a near-term commercialization cash bridge. Neither is a better-defined long payoff than IRDM’s merger terms, and none clears the Desk hurdle.

The IRDM countercase is credible: the vote is complete, directors support the deal, and Rocket Lab said on Sep. 15 that it had completed a $1.944 billion gross ATM sale (29.3 million shares) and arranged to use the proceeds, Iridium’s $1.775 billion term loan and other available cash to fund consideration and certain debt repayment; the initial $3.6 billion bridge commitment was terminated. Yet regulatory approvals remain, the stock portion is volatile, and the expected close is about nine months away. Funding is substantially de-risked; the residual spread is still not an executable, risk-bounded arbitrage.

Why This Can Move More Than 5% Soon

The next material repricing can come from (1) HSR clearance, (2) FCC consent to transfer specified telecom authorizations, (3) remaining specified foreign investment/satellite/telecom approvals, or (4) a delay, adverse order, financing change, or termination. Approval progress can compress the risk discount; a blocked or delayed approval can reprice IRDM toward a standalone value that is not established by the $54 transaction headline.

The completed regular-session close was $48.89. A later after-hours source showed $48.72; that observation was slightly below the regular close, not evidence of a fresh market acceptance. A closing announcement is expected only around mid-2027, subject to conditions. The calendar itself creates capital opportunity cost even if the transaction eventually closes.

10/5 Asymmetry Gate

Test	Reference-only result from IRDM’s $48.72 after-hours mark
Favorable base-case move	+10.8% to nominal $54 consideration
Credible adverse scenario	-41.5% to the $28.52 pre-speculation standalone reference
Gross base reward / adverse risk	0.26:1
Base versus carry alternative	About +7.4% versus a simple nine-month Treasury terminal value, before costs and taxes
Approximate nine-month Treasury carry benchmark	3.18% simple at the Sep. 24 three-month par yield of 4.24%; reinvestment is an assumption
Classification	Reject / no trade

The nominal base reaches +10% gross, but it is reference-only, depends on completion and an in-collar closing VWAP, and is not a verified executable entry. After carry, the base is about +7.4%; the adverse stress is much larger than 5%, and the reward/risk ratio is below 2:1. With the financing package substantially de-risked, the probability-weighted terminal value is only about 0.4% above the illustrative Treasury carry benchmark before transaction costs and taxes.

What Should Surprise the Reader

The contract’s collar protects the nominal stock-leg value only when the final 10-day RKLB VWAP falls within $67.50-$112.50. Inside that range, the exchange ratio is $27 divided by the VWAP, so the stock portion is nominally $27 at that VWAP. At or below $67.50 the ratio is fixed at 0.4000, exposing IRDM holders to more downside in RKLB; at or above $112.50 it is fixed at 0.2400, allowing greater upside if RKLB continues higher. The reference RKLB closes were $73.61 regular and $74.31 after hours, but neither predicts the future closing VWAP or closing-day market price.

The new vote therefore reduces one discrete risk without making consideration fixed. It also does not alter the SEC filing’s remaining conditions: HSR, FCC, specified foreign approvals, absence of prohibitory orders/material adverse effects, and listing/effectiveness mechanics for the shares to be issued.

Rocket Lab’s Sep. 15 financing update also reduced funding risk, but it did so in part by issuing 29.3 million shares to raise $1.944 billion gross; the $1.775 billion Iridium term loan remains in the post-close financing structure. Neither financing evidence nor the vote alters the remaining regulatory conditions.

The Setup

Fact: On Sep. 24, Iridium reported that 99.6% of votes cast approved the deal, representing 81.0% of outstanding shares entitled to vote. The issuer says the transaction is expected to close by mid-2027, subject to remaining approvals and customary conditions.

Fact: The June 28 merger agreement provides $27 cash plus an exchange-ratio-based Rocket Lab share amount. The ratio is 0.4000 if the contract’s RKLB ten-day VWAP is at or below $67.50; $27 divided by that VWAP between $67.50 and $112.50; and 0.2400 at or above $112.50. The stated $54 total is therefore nominal in the central band, not a guaranteed cash payment.

Fact and unknown: The transaction is intended to qualify as a tax-free reorganization only if the relative value of stock and cash consideration meets specified tax conditions. Iridium’s June 29 filing states that if those conditions are not met, the subsequent merger will not occur and the transaction will not qualify as tax-free. The closing-time stock value and resulting tax treatment remain unknown.

Fact: Rocket Lab’s Sep. 15 Form 8-K said its ATM program had raised approximately $1.944 billion gross through issuance of about 29.3 million RKLB shares; Rocket Lab reported the proceeds, Iridium’s $1.775 billion term loan and other available cash as sufficient for the cash consideration, certain debt repayment and related costs. The $3.6 billion bridge commitment was terminated. The lender amendment lets Iridium’s existing term loans remain after close; their interest margin steps to SOFR plus 2.50%-3.00% (or base rate plus 1.50%-2.00%) based on ratings. This is material funding progress and simultaneous buyer dilution/debt carry, not proof of closing.

Inference: The vote result and completed cash financing make completion more likely than before the meeting, but do not answer whether remaining regulatory approvals arrive on schedule or whether the stock component retains value. The approval announcement came after months of public deal disclosure, so a vote result that was widely expected may already be reflected in the price; market timing around the news cannot be inferred from a +1.22% daily close alone.

Unknown: I do not have a current, source-verified probability of HSR/FCC/foreign clearance, a live synchronized hedge ratio, post-approval short interest/borrow, executable spread and depth, or a reliable standalone valuation after deal failure. The $28.52 stress anchor is the IRDM share price cited in the S-4 as of Apr. 1, before merger-market speculation. It is a historical reference, not a forecast, floor, or current unaffected price.

The Market Price

IRDM’s Sep. 24 regular close was $48.89, up 1.22% on 587,658 shares; a later extended-hours observation was $48.72 at 7:45 p.m. EDT. The current research timestamp is overnight before the Sep. 25 U.S. session. These are reference values only. No current regular-session bid/ask, spread, depth, venue quality, volume quality or realistic exit size was verified.

RKLB’s Sep. 24 regular close was $73.61, up 4.69% on 24.9 million shares; its later after-hours source mark was $74.31 at 7:59 p.m. EDT. Do not combine those timestamps as if they were an executable pair. The actual exchange ratio will use a future ten-day VWAP ending shortly before completion, not either current mark.

The Mispricing

The disagreement is between the market’s roughly $48.72 after-hours IRDM mark and the transaction’s nominal $54 value, conditional on completion and a closing VWAP in the collar. The gross reference spread is $5.28 per share, or 10.8%. That is not a riskless price difference: the close target is mid-2027, the stock leg remains exposed to RKLB, and any termination reopens the question of standalone value.

The same risk that creates the apparent spread explains why it may be deserved. A low market price may reflect remaining regulatory uncertainty, the time value of money, the threat of RKLB volatility outside the collar, tax/structure conditions and the material mark-to-market loss if the transaction fails. The $54 notional headline is not sufficient evidence that the market is mispricing those states.

The Positioning

The shareholder vote is direct evidence of support, not evidence of current trading crowding. The 81% figure is the portion of outstanding shares entitled to vote represented by votes for the proposal; it is not an institutional ownership or short-interest statistic. Current short interest, securities lending utilization/recall, options positioning, dealer exposure and fund flows were not verified. No forced covering or merger-arbitrage accumulation is assumed.

The Catalyst

Iridium shareholder vote, Sep. 24: completed; 99.6% of votes cast supported adoption. The cheapest test is the next regular-session IRDM price and volume compared with the $48.89 close and $48.72 after-hours reference.
Antitrust and communications approvals: still required under the agreement, including HSR waiting-period expiration/termination and FCC consent to transfer certain licenses, plus specified foreign investment, satellite and telecom approvals. The companies’ “mid-2027” close remains a target, not a completed step.
Closing VWAP and share ratio: only the ten-trading-day VWAP ending two full trading days before completion determines the ratio. Rebuild consideration using the actual VWAP and current RKLB price when observable; do not treat today’s 73.61 close as that future measurement.
Failure/delay path: the agreement has an initial June 28, 2027 end date, with possible extensions to Sep. 28 and Dec. 28 under specified conditions. A final blocking order or termination would remove the transaction reference and require standalone valuation.

Cheapest falsification test: the next filed regulatory/closing update. If HSR, FCC or any specified foreign approval is denied, subject to onerous conditions, or does not progress on the stated path, the “vote completion materially de-risks the spread” view is wrong. If approvals clear quickly, that lowers one risk but still does not validate the stock leg or 10/5 geometry.

The Payoff

This is a per-share merger-consideration scenario map, not a valuation of the combined company and not a hedge recommendation. The expected holding window is approximately nine months to the stated mid-2027 target close. Scenario values are gross, use the $48.72 after-hours IRDM reference, assume no dividends or taxes, and do not establish executable pricing.

For the base, assume the merger closes and the final ten-day VWAP lies within the $67.50-$112.50 collar; in that band the stock portion is nominally worth $27 at the VWAP measurement, giving $54 total. This assumes the closing-day market value of the stock leg is approximately its VWAP measurement. For the top case, assume RKLB has a $125 close-time stock price and a final VWAP at or above $112.50; the 0.2400 ratio makes the stock leg $30 and total consideration $57. For the bottom case, assume the merger fails and IRDM revisits $28.52, its cited Apr. 1 pre-speculation reference. The bottom is a stress, not a claim about today’s standalone fair value. Probabilities are analyst judgments, not observed frequencies: 10% top, 75% base, 15% bottom. Strong vote support and completed cash financing favor completion; multiple regulatory approvals and the long closing window still warrant a meaningful failure/delay tail.

At a 4.24% Sep. 24 three-month Treasury par yield, a simple nine-month carry benchmark is approximately 3.18%, or about $1.55 on $48.72. This assumes the rate can be rolled and is not a guaranteed investor return. The Treasury comparison is an opportunity-cost sensitivity, not part of the merger consideration.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	10%	$57.00	+17.0%	Through mid-2027, about nine months	Deal closes; final RKLB VWAP is at/above $112.50; RKLB share price at exchange is $125 so 0.2400 shares are worth $30	Low: illustrative high-volatility acquirer-stock path
Base Case	75%	$54.00	+10.8%	Same horizon	Deal closes; ten-day VWAP remains inside the collar and closing-date RKLB price is near that VWAP	Medium-low: terms and vote are verified, but approvals/timing/price remain future states
Bottom Case	15%	$28.52	-41.5%	Same horizon	Deal terminates/fails and IRDM revisits its Apr. 1 pre-speculation price	Low: dated historical reference, not a current standalone valuation
Invalidation	n/a	No numeric entry threshold	N/A	Any time before close	Deal terms change, required approval fails, termination notice is filed, or actual consideration materially diverges from the in-collar assumption	High for filed event/term changes; low for market value impact

Probability-weighted expected value: $50.48, or +3.6% versus $48.72 before costs and carry. Against a simple 3.18% nine-month Treasury carry benchmark (terminal value about $50.27), the map is only about 0.4% higher before costs and taxes.

Current market level and timestamp: IRDM $48.72 at Sep. 24, 2026, 7:45 p.m. EDT after hours; latest completed regular close $48.89 at 4:00 p.m. EDT. RKLB references are separately timestamped above.

Primary instrument: IRDM common stock only, reference analysis; not a paired or hedged trade.

10/5 favorable base move: +10.8% gross from after-hours reference, before carry.

10/5 credible adverse move: -41.5% in the deal-break stress.

10/5 measurement basis: reference-only; no current executable entry.

10/5 status: Reject.

Confidence: Medium on contract/vote facts; low on closing probability, standalone downside and final stock-leg value.

The Kill Shot

The strongest counterparty case is that the vote was nearly unanimous among votes cast, 81% of eligible shares actually supported it, Rocket Lab reports it has completed ATM financing for the cash leg, the lenders consented to the remaining term-loan structure, and the primary registration materials set a clear exchange ratio. This makes completion plausible and turns nominal $54 consideration into a visible anchor.

The load-bearing weak point is the difference between a nominal consideration formula and a guaranteed cash payoff. HSR, FCC and specified foreign approvals are outstanding; the time to closing is long; the stock leg is protected to a nominal $27 at the VWAP measurement only inside the collar, while outside the lower boundary it takes more downside and above the upper boundary it can gain more upside; and failed-deal standalone value is uncertain. Even using a completion-favoring 85% probability across the top/base cases, a 15% break state leaves expected value only about 0.4% over the Treasury carry benchmark before costs. After that attack, IRDM is Reject/no trade.

What Could Go Wrong

A regulatory approval is delayed, denied or conditioned in a way that changes the economics; the merger is terminated or the end date is extended.
The agreement’s intended tax-free two-step reorganization depends on the relative value of stock and cash consideration meeting specified tax conditions; the 8-K says the subsequent merger would not occur if those conditions are not met.
Rocket Lab’s completed $1.944 billion ATM issuance funds the cash leg but has already added approximately 29.3 million shares to RKLB’s denominator; the surviving $1.775 billion Iridium term loan remains a post-close obligation with amended interest terms.
Rocket Lab’s share price or final 10-day VWAP falls below $67.50, fixing the ratio at 0.4000 and exposing the stock leg to further downside.
RKLB’s close-time price diverges from the VWAP used to set the ratio; the collar does not fully insulate shareholders from the resulting mismatch.
Closing fails and IRDM’s stand-alone market value is materially below the $28.52 historical stress reference.
A long cash commitment earns less than the illustrative Treasury benchmark, actual closing slips, or transaction taxes/fees consume return.
Thin overnight trading, a gap, halt or unverified exit liquidity makes any observed reference price unavailable for execution.

What Would Prove This Wrong

The no-trade conclusion would be too conservative if required approvals arrive materially ahead of schedule, the ten-day RKLB VWAP and closing price produce a stable consideration value, IRDM’s current regular-session price remains sufficiently below that value after time-value and realistic transaction costs, and the standalone break case can be evidenced as no worse than the Desk’s adverse bound. That is not established by shareholder approval alone.

Risk Audit

The $27 cash leg is contractual only if the transaction closes. It does not protect the other half of the package from a lower RKLB market price, does not pay interest while holders wait, and does not turn merger failure into a $27 redemption. Rocket Lab reports its cash consideration funding as substantially complete, but the funding came through a large ATM share issuance and the amended Iridium term loan remains. The agreement specifies a $223.62 million termination fee owed by Iridium to Rocket Lab only in certain circumstances; that fee does not compensate ordinary shareholders for a deal break. The cash-and-stock value is therefore exposed to transaction, acquirer-price, timing, tax-structure and liquidity risks.

Best Trade Strategy

No trade. Keep entry.price=null and execution.can_execute=false. Reassess after the next filed HSR/FCC/foreign-approval update and a completed regular-session IRDM quote. A fresh screen must recalculate the consideration from the contract’s actual final ten-day VWAP, current RKLB market price, expected settlement window, and a defensible standalone failure case. This article models unhedged IRDM common for long-only research; it does not recommend shorting RKLB, using options, leverage, margin, market orders or price floors.

Sources

Iridium and Rocket Lab: Sep. 24 shareholder approval, issuer release; vote count, conditions and mid-2027 target.
Iridium Form 8-K and June 28 merger agreement, SEC filing; $27 cash, ratio collar, approvals, end dates and conditional termination fee.
Rocket Lab Form S-4 / Iridium proxy statement, issuer-filed registration/proxy materials; full merger mechanics and Apr. 1 pre-speculation $28.52 reference.
Rocket Lab Sep. 15 financing Form 8-K and attached release, SEC filing; completed $1.944B gross ATM issuance of about 29.3M shares, continued $1.775B Iridium term loan, lender consent and termination of the original $3.6B bridge commitment.
IRDM Sep. 24 historical prices, market-data page attributed to S&P Global Market Intelligence; close, OHLC and volume.
RKLB Sep. 24 historical prices, market-data page attributed to S&P Global Market Intelligence; close, OHLC and volume.
U.S. Treasury daily par-yield curve, Sep. 24, 2026, 3-month par yield used only for the carry benchmark.
Select Water Solutions announces Pilot Water acquisition, issuer release, Sep. 24; WTTR candidate screen only.
WTTR Sep. 24 closing reference, market-data candidate source; close $19.53, 2.02M shares.
WTTR Sep. 24 daily close/volume history, S&P Global Market Intelligence data; close $19.53, reported volume 1.70M shares.
Archer HSR waiting-period announcement and 8-K exhibit, issuer-filed release dated Sep. 24; ACHR candidate screen only.
ACHR Sep. 24 price history, candidate market-data source; delayed closing feeds differ.
ACHR Sep. 24 closing reference, secondary candidate source; close $5.71 and volume 28.68M shares.

Research Quality Scorecard

Criterion	Score	Evidence and deduction
Market disagreement	4/5	New vote support versus a >9-month close path and a volatile share component; vote may already be priced
Evidence base	4/5	Filed merger formula and same-day vote release; remaining approval probability not observed
Positioning and flows	2/5	Vote data are known, but current holder concentration, short, borrow, options and flows are missing
Catalyst path	4/5	Approval ladder and vote are observable; timeline remains conditional
Payoff architecture	2/5	Formula is contractual, but failure value and probability are uncertain and carry consumes the spread
Invalidation discipline	4/5	Regulatory orders, termination, VWAP and closing price are monitorable
Differentiated insight	4/5	Separates cash consideration from the VWAP-set stock leg and compares with time-value benchmark
Client value	4/5	Shows why an approved deal and nominal $54 headline still fail the long 10/5 test
Total	28/40	No-trade screen; failed adverse-risk and reward/risk gates override the score

Bottom Line

IRDM’s vote approval is a real milestone, and Rocket Lab’s completed ATM makes funding clearer than the merger headline alone suggests. But at $48.72, the nominal $54 in-collar payoff leaves only about 7.4% above a simple nine-month carry benchmark; the subjective map is just 0.4% above carry before costs and taxes, the break stress is -41.5%, and gross reward/risk is 0.26:1. The rational update is higher completion confidence, not a claim that the residual spread is mispriced or executable.

AI Illustration Prompt

Create a restrained financial-editorial illustration for The Mispricing Desk about Iridium’s Sep. 24, 2026 shareholder approval of Rocket Lab’s acquisition. Show one IRDM share ticket splitting into “$27 CASH, ONLY AT CLOSE” and a Rocket Lab share ticket stamped “10-DAY VWAP; VARIABLE RATIO.” Draw the collar as a clean brass measuring rail: “<= $67.50: 0.4000 SHARES,” “$67.50-$112.50: $27 / VWAP,” “>= $112.50: 0.2400 SHARES.” Place an approval card “99.6% OF VOTES CAST / 81.0% OF ELIGIBLE SHARES” and an ATM funding card “$1.944B GROSS / 29.3M SHARES ISSUED / $1.775B TERM LOAN REMAINS” beside a queue of uncompleted stamps “HSR / FCC / FOREIGN APPROVALS.” Include market references “IRDM REGULAR CLOSE $48.89 / AFTER-HOURS $48.72” and “RKLB REGULAR CLOSE $73.61 / AFTER-HOURS $74.31,” clearly not an order ticket. Show three scenario cards “TOP $57 / 10%,” “BASE $54 / 75%,” “BREAK STRESS $28.52 / 15%,” with “BASE +10.8% / ADVERSE -41.5% / REJECT.” In the foreground compare the scenario-weighted value with a subtle Treasury line “9-MONTH CARRY BENCHMARK ~3.18%; WEIGHTED VALUE ONLY ~0.4% ABOVE.” Use satellite-network geometry, an understated legal folder, slate navy, warm paper, graphite, and one muted brass accent; no rocket-launch cliché, no invented logos, no generic candlesticks. Add a small readable “The Mispricing Desk” watermark. Wide 16:9 composition.